SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2014 / Cilt: 44 - Sayı: 6

Investigation of serum macrophage migration inhibitor factor and monocyte chemotactic protein-1 levels in irritable bowel syndrome

Feti TÜLÜBAŞ
Mustafa ORAN
Rafet METE
Filiz TURAN
Ahsen YILMAZ
Zeynep Deniz YILDIZ
Ahmet GÜREL
Pages
967–971
Publication Date
2014-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: These results show that alterations in MMIF and MCP-1 affect the proinflammatory process.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Irritable bowel syndrome (IBS), a functional disorder of the bowel, has been thought to result from immune activation.
📊
Key Findings & Data:The aim of this study was to evaluate macrophage migration inhibitory factor (MMIF) and monocyte chemotactic protein-1 (MCP-1) levels in IBS patients.
💡
Conclusion & Impact:Conclusion: These results show that alterations in MMIF and MCP-1 affect the proinflammatory process.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Irritable bowel syndrome · macrophage migration inhibitory factor · monocyte chemotactic protein

Abstract

Irritable bowel syndrome (IBS), a functional disorder of the bowel, has been thought to result from immune activation. The aim of this study was to evaluate macrophage migration inhibitory factor (MMIF) and monocyte chemotactic protein-1 (MCP-1) levels in IBS patients. Materials and methods: We enrolled 30 IBS patients and 30 healthy controls. The MMIF and MCP-1 levels of all patients and controls were detected using commercial enzyme-linked immunosorbent assay kits. Results: Serum MMIF and MCP-1 levels were markedly higher in IBS patients than in controls. White blood cell, neutrophil, lymphocyte, monocyte, eosinophil, and basophil counts did not differ significantly between groups. Conclusion: These results show that alterations in MMIF and MCP-1 affect the proinflammatory process. They also suggest that MMIF and MCP-1 may play a substantial role in IBS.

Özet

Irritable bowel syndrome (IBS), a functional disorder of the bowel, has been thought to result from immune activation. The aim of this study was to evaluate macrophage migration inhibitory factor (MMIF) and monocyte chemotactic protein-1 (MCP-1) levels in IBS patients. Materials and methods: We enrolled 30 IBS patients and 30 healthy controls. The MMIF and MCP-1 levels of all patients and controls were detected using commercial enzyme-linked immunosorbent assay kits. Results: Serum MMIF and MCP-1 levels were markedly higher in IBS patients than in controls. White blood cell, neutrophil, lymphocyte, monocyte, eosinophil, and basophil counts did not differ significantly between groups. Conclusion: These results show that alterations in MMIF and MCP-1 affect the proinflammatory process. They also suggest that MMIF and MCP-1 may play a substantial role in IBS.

🔖

Cite This Article

TÜLÜBAŞ, F., ORAN, M., METE, R., TURAN, F., YILMAZ, A., YILDIZ, Z. D., GÜREL, A. (2014). Investigation of serum macrophage migration inhibitor factor and monocyte chemotactic protein-1 levels in irritable bowel syndrome. Turkish Journal of Medical Sciences, Cilt: 44 - Sayı: 6, 967–971. https://ajindex.com/articles/212935

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Philpott H, Gibson P, Thien F. Irritable bowel syndrome - An inflammatory disease involving mast cells. Asia Pac Allergy 2011; 1: 36–42. 2. O’Malley D, Quigley EM, Dinan TG, Cryan JF. Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome? Brain Behav Immun 2011; 25: 1333–1341.
  2. Schwetz I, Bradesi S, Mayer EA. Current insights into the pathophysiology of irritable bowel syndrome. Curr Gastroenterol Rep 2003; 5: 331–336.
  3. Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J. High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 1999; 264: 751–758.
  4. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R. MIF is a pituitary- derived cytokine that potentiates lethal endotoxaemia. Nature 1993; 365: 756–759.
  5. Fan H, Hall P, Santos LL, Gregory JL, Fingerle-Rowson G, Bucala R, Morand EF, Hickey MJ. Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase. J Immunol 2011; 186: 4915–4924.
  6. Meyer-Siegler KL, Leifheit EC, Vera PL. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 2004; 4: 34. Jemaa R, Rojbani H, Kallel A, Ben Ali S, Feki M, Chabrak S, Elasmi M, Taieb SH, Sanhaji H, Souheil O et al. Association between the -2518G/A polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene and myocardial infarction in Tunisian patients. Clini Chim Acta 2008; 390: 122–125.
  7. Piemonti L, Leone BE, Nano R, Saccani A, Monti P, Maffi P, Bianchi G, Sica A, Peri G, Melzi R et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002; 51: 55–65.
  8. Drossman DA, Dumitrascu DL. Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis 2006; 15: 237–241.
  9. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32–39.
  10. Arevalo F, Aragon V, Montes P, Guzman E, Monge E. Increase of intraepithelial lymphocytes in patients with irritable bowel syndrome. Rev Gastroenterol Peru 2011; 31: 315–318 (article in Spanish with abstract in English). Lee KJ, Kim YB, Kim JH, Kwon HC, Kim D